Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy

NCT ID: NCT01870219

Last Updated: 2013-06-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-02-29

Study Completion Date

2013-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to evaluate the effect of sevoflurane or ketamine on the QTc and Tp-e interval during in patients with major depression.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients enrolled in the study are randomly allocated by computer-generated random numbers to receive either sevoflurane or ketamine for their initial ECT session. They subsequently receive an alternative study drug in their next session, continuing to alternate between drugs at each session until the sixth session. In group S, sevoflurane are initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus is delivered, In group K, ketamine are given to 1mg/kg ıv bolus.

Electrical stimulus is delivered via bilateral frontotemporal electrodes.The mean arterial pressure (MAP), HR, and ECG are recorded before anesthetic induction (T1), after anesthetic induction (T2) and at 0, 1, 3, 10 min after the seizure ended (T3, T4, T5 and T6, respectively).The QT interval and Tp-e interval are measured by one author, who was unaware of group allocation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Major Depression Electroconvulsive Therapy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group S

In group S, sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered, at which time it was turned off.

Group Type ACTIVE_COMPARATOR

Sevoflurane

Intervention Type DRUG

sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered

Group K

In group K, ketamine was given to 1mg/kg ıv bolus.

Group Type ACTIVE_COMPARATOR

Ketamine

Intervention Type DRUG

ketamine was given to 1mg/kg ıv bolus

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sevoflurane

sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered

Intervention Type DRUG

Ketamine

ketamine was given to 1mg/kg ıv bolus

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Volatile agent Intravenous anesthetic agent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Unpremedicated
* American Society of Anesthesiologists (ASA) I-II the patients
* Major depressions patients scheduled for ECT sessions

Exclusion Criteria

* pregnant
* with permanent pacemakers,
* diabetes mellitus,
* atrial fibrillation,
* electrolyte imbalance,
* patients taking antiarrhythmics and β-blockers.
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Inonu University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Feray Erdil

MD

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Feray Erdil, MD

Role: PRINCIPAL_INVESTIGATOR

Associated Prof Dr

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Turgut Ozal Medical Center

Malatya, , Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Erdil F, Demirbilek S, Begec Z, Ozturk E, Ersoy MO. Effects of propofol or etomidate on QT interval during electroconvulsive therapy. J ECT. 2009 Sep;25(3):174-7. doi: 10.1097/YCT.0b013e3181903fa5.

Reference Type BACKGROUND
PMID: 19225403 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Turgut Ozal Medical Center

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Pro-Epileptic Effects of IV Ketamine
NCT06741930 COMPLETED PHASE4
Ketamine Versus Propofol as ICU Sedation
NCT06243822 COMPLETED PHASE4
Sevoflurane Induced Emergence Agitation
NCT02022488 COMPLETED PHASE4
Ketamine and Propofol for Upper Endoscopy
NCT02295553 COMPLETED PHASE4